Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electronic Training for [18F]Flutemetamol PET Interpretation
NCT01672827Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Jul 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of flutemetamol in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by GE HealthCare. Started Jul 2012; status: completed.
02
Drugs
flutemetamol
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01672827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01672827.